allo-APZ2-OTS

DRUG3 trials

Sponsors

Rheacell GmbH & Co. KG, RHEACELL GmbH & Co. KG

Conditions

Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epidermolysis Bullosa (JEB)

Phase 3

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)

Active, not recruitingNCT05464381

RHEACELL GmbH & Co. KGEpidermolysis Bullosa

Start: 2023-06-13End: 2027-01-31Updated: 2025-12-10

A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB)

RecruitingCTIS2022-500266-10-00

Rheacell GmbH & Co. KGRecessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epidermolysis Bullosa (JEB)

Start: 2023-06-13Target: 119Updated: 2025-12-02

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

Active, not recruitingNCT05838092

RHEACELL GmbH & Co. KGEpidermolysis Bullosa

Start: 2023-10-18End: 2026-07-31Updated: 2025-12-10